This year's best-performing technology stock AMD was also crushed
On Monday, AMD shares fell 9.5% after an insider sold off the company's stock. On Monday, local time, the company's share price once fell to 18.80 US dollars, the last transaction price of the day was 19.03 US dollars. Approximately 95,744,953 shares were traded in midday trading, an increase of 16% over the average daily volume of 82,308,492.
Specifically, insider Mark D. Papermaster sold 311,962 AMD shares on Thursday, August 16th. The average selling price of the stock is $19.59 and the total transaction price is $611,133.58.
In addition, the company's chief financial officer Devinder Kumar sold 258,622 shares of AMD shares on Thursday, August 16. The average selling price of these stocks is $19.51, with a total value of $504,571.52.
In the past three months, insiders sold a total of 2,529,209 AMD shares worth $56,688,490. 1.80% of the shares are held by insiders of the company.
At the end of August, foreign media reported that AMD is the hottest stock this year and the best performing technology stock in the 2018 S&P 500 index. Since January this year, the company's share price has risen by 146%, far exceeding Abiomed, the second-best performer in the S&P 500. The latter's share price has risen by 105%.
Specifically, insider Mark D. Papermaster sold 311,962 AMD shares on Thursday, August 16th. The average selling price of the stock is $19.59 and the total transaction price is $611,133.58.
In addition, the company's chief financial officer Devinder Kumar sold 258,622 shares of AMD shares on Thursday, August 16. The average selling price of these stocks is $19.51, with a total value of $504,571.52.
In the past three months, insiders sold a total of 2,529,209 AMD shares worth $56,688,490. 1.80% of the shares are held by insiders of the company.
At the end of August, foreign media reported that AMD is the hottest stock this year and the best performing technology stock in the 2018 S&P 500 index. Since January this year, the company's share price has risen by 146%, far exceeding Abiomed, the second-best performer in the S&P 500. The latter's share price has risen by 105%.